<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>form8k801ex991dec-17.txt
<DESCRIPTION>EXHIBIT 99.1
<TEXT>





                                  EXHIBIT 99.1




<PAGE>



8229 Boone Boulevard, Suite 802                              COMPANY CONTACT:
Vienna, VA  22182.  placecountry-regionUSA                   Gavin de Windt
Telephone (703) 506-9460                                     CEL-SCI Corporation
www.cel-sci.com                                              (703) 506-9460

      CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING
          COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

VIENNA,  VA,  December  7, 2017 --  CEL-SCI  Corporation  (NYSE  American:  CVM)
announced today that the Independent  Data Monitoring  Committee  (IDMC) for the
Company's  pivotal  Phase 3 head and neck  cancer  study of its  investigational
immunotherapy  Multikine* (Leukocyte  Interleukin,  Injection) has completed its
review of the Phase 3 study data.  The data from all 928 enrolled  patients were
provided to the IDMC by the clinical research organization (CRO) responsible for
data management of this Phase 3 study.

The IDMC made the following observation and recommendation:

      a) The IDMC saw no evidence of any significant safety questions.

      b) The IDMC recommends continuing the study.


IDMCs are committees commonly used by sponsors of clinical trials to protect the
interests of the patients and the integrity of the study data in ongoing trials,
especially when the trials involve patients with life threatening diseases,  and
when, as in cancer clinical trials, they extend over long periods of time. About
CEL-SCI Corporation

CEL-SCI  is a Phase 3 cancer  immunotherapy  company.  When it  comes to  cancer
immunotherapy, CEL-SCI believes it is most logical to boost the patient's immune
system while it is still intact in order to have the greatest possible impact on
survival.  Therefore,  CEL-SCI treats patients who are newly diagnosed with head
and neck cancer with its lead investigational  immunotherapy  Multikine,  BEFORE
they have received  surgery,  radiation  and/or  chemotherapy.  This approach is
unique.  Most other  cancer  immunotherapies  are used only  after  conventional
therapies have been tried and/or failed.  Head and neck cancer  represents about
6% of all cancers.  Multikine has received Orphan Drug  designation from the FDA
for the treatment of head and neck cancer  patients with advanced  squamous cell
carcinoma.

The Company's LEAPS  technology is being developed as a therapeutic  vaccine for
rheumatoid  arthritis and is supported by grants from the National Institutes of
Health. CEL-SCI has patents on Multikine from the US, Europe, China, and Japan.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

                                       1
<PAGE>

Forward-Looking Statements

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans" and  "expects,"  and
similar expressions,  are intended to identify forward-looking  statements. Such
statements  are  subject  to risks and  uncertainties  that could  cause  actual
results to differ  materially from those projected.  Factors that could cause or
contribute to such differences  include,  an inability to duplicate the clinical
results  demonstrated in clinical studies,  timely  development of any potential
products  that  can be  shown  to be safe  and  effective,  receiving  necessary
regulatory  approvals,  difficulties  in  manufacturing  any  of  the  Company's
potential  products,  inability  to raise  the  necessary  capital  and the risk
factors set forth from time to time in CEL-SCI's filings with the Securities and
Exchange  Commission,  including  but not limited to its report on Form 10-K and
10-K/A  for the year  ended  September  30,  2016.  The  Company  undertakes  no
obligation   to  publicly   release   the  result  of  any   revision  to  these
forward-looking   statements  which  may  be  made  to  reflect  the  events  or
circumstances   after  the  date  hereof  or  to  reflect  the   occurrence   of
unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has
registered  for  this  investigational  therapy,  and this  proprietary  name is
subject  to FDA  review in  connection  with the  Company's  future  anticipated
regulatory submission for approval.  Multikine has not been licensed or approved
for  sale,  barter  or  exchange  by the  FDA or any  other  regulatory  agency.
Similarly,  its  safety  or  efficacy  has not  been  established  for any  use.
Moreover,  no  definitive   conclusions  can  be  drawn  from  the  early-phase,
clinical-trials  data involving the investigational  therapy Multikine.  Further
research is required,  and early-phase  clinical trial results must be confirmed
in the  Phase 3  clinical  trial  of  this  investigational  therapy  that is in
progress.
</TEXT>
</DOCUMENT>
